Czech Multicentre Research Database of Chronic Obstructive Pulmonary Disease (COPD)

Czech Multicentre Research Database of Chronic Obstructive Pulmonary Disease (COPD): Registry of the Czech Pneumological Society (CPPS) at the Czech Medical Association (CzMA)

The chronic obstructive pulmonary disease (COPD) is the occurrence of chronic bronchitis or emphysema, a pair of commonly co-existing diseases of the lungs in which the airways narrow over time. This limits airflow to and from the lungs, causing shortness of breath (dyspnoea). In clinical practice, COPD is defined by its characteristic airflow limitation on lung function tests. In contrast to asthma, this limitation is poorly reversible and usually gets increasingly worse over time.

The COPD registry is a non-interventional multicentre observational prospective database focusing on the collection and analysis of data on real mortality and morbidity in COPD population of the Czech Republic population of COPD patients. Monitoring is done at the occasion of regular check-ups, followed by retrospective search of data in the documentation, and a record into the registry.

The aim of Czech National Research Database of Chronic Obstructive Pulmonary Disease is to establish the clinical course of severe forms of COPD, establish the cause for deterioration of clinical status of our patients and describe the progression of COPD to death.

The registry fulfils general objectives of health registries such as monitoring of causes, development, treatment and consequences of a severe disorder, including economic and social impacts. Statistical and scientific analyses of the registry data are focused, in particular, on the assessment of health determiners of the selected patient cohort with the aim to improve health status of the patients.

Study Overview

• Status: Unknown
• Conditions: Chronic Obstructive Airway Disease

Detailed Description

Chronic Obstructive Pulmonary Disease (COPD) is a treatable and preventable clinically heterogeneous syndrome with dominant respiratory symptoms and various systemic consequences. The incidence of COPD is increasing worldwide. In general, COPD is caused by a prolonged inflammatory reaction of a genetically predisposed individual exposed to long-term inhalation of air pollution, harmful particles and gases. This disease has a negative progression in time even after end of exposure. The pulmonary component is associated with expiratory airflow limitation, which is not fully reversible. The airflow limitation in COPD develops gradually as a result of chronic, primarily non-infectious inflammation of the airways and lung parenchyma. Systemic consequences are often found in cardiovascular, musculoskeletal and other systems. COPD can be considered a proven pre-cancerous condition.

Up-to-date and precise clinical and epidemiological data describing the situation in the Czech Republic is currently unavailable. The Czech Republic still does not have any data on representation of different phenotypes among COPD patients.

The COPD Register is a non-interventional multicenter observational prospective database focusing on the collection and analysis of data on real mortality and morbidity in an unselected (consecutive) population of patients with severe forms of COPD (post-bronchodilator FEV1≤ 60%). Monitoring is done at the occasion of regular check-ups, followed by retrospective search of data in the documentation, and a record into the registry subsequently.

The main purposes of this study:

• Assessment of all-cause mortality
• Assessment of morbidity:

(A) acute exacerbation of COPD (B) acute non-COPD respiratory events (C) acute non-respiratory events (D) cancers (E) ischemic heart disease (infarct, angina pectoris, congestive heart failure and arrhythmia)

Other aims of this study:

• Monitoring of lung function decline (post-bronchodilator FEV1)
• Monitoring of prognostic indices
• COPD categories and quality of life
• Evaluation of activity of daily living

• Assessment of therapeutic compliance

  • Note: MMAS-4 questionnaire by Prof. Donald E. Morisky will not be used as of September 2018
• Analysis of extra-pulmonary impairment during

• Study Type: Observational
• Enrollment (Actual): 813

Contacts and Locations

Study Locations

• Czechia
  • Brno, Czechia, 625 00
    • University Hospital Brno
  • Ceské Budějovice, Czechia
    • Hospital České Budějovice
  • Hradec Kralove, Czechia, 500 05
    • University Hospital Hradec Kralove
  • Jihlava, Czechia, 586 33
    • Hospital Jihlava
  • Liberec, Czechia, 460 63
    • Regional Hospital Liberec
  • Mlada Boleslav, Czechia
    • Regional hospital Mlada Boleslav
  • Olomouc, Czechia, 775 20
    • University Hospital Olomouc
  • Ostrava, Czechia, 708 52
    • University Hospital Ostrava
  • Plzen, Czechia, 301 00
    • EUC Klinika Plzen
  • Prague, Czechia, 140 59
    • Thomayer Hospital
  • Prague, Czechia, 150 06
    • University Hospital in Motol
  • Prague, Czechia, 180 81
    • Hospital Na Bulovce
  • Usti nad Labem, Czechia, 401 13
    • Masaryk hospital in Usti nad Labem
  • Zlin, Czechia, 760 01
    • Tomas Bata Regional Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

The COPD registry is a non-interventional multicentre observational prospective database focusing on the collection and analysis of data on real mortality and morbidity in an unselected population of COPD patients in long lasting care of individual participating centres. Each centre covers the population of a certain county. The centres are localized as to symetrically cover the entire Czech Republic.

Description

Inclusion Criteria:

• Post-bronchodilator FEV1/VC < LLN and post-bronchodilator FEV1 ≤ 60% of the predicted value (VC - Vital Capacity, LLN - Lower Limit of Normal)
• Definite clinical diagnosis of COPD (can be overlaps: COPD + asthma / COPD + bronchiectasis)
• Stable course of COPD (≥ 8 weeks free of acute exacerbations and/or free of any acute conditions)
• Informed consent

Exclusion Criteria:

• "Pure" bronchial asthma without COPD
• "Pure" bronchiectasis without COPD
• Cystic fibrosis
• End-stage of COPD
• Non-curable malignancy
• Total non-compliance
• Immobility

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of all-cause mortality	Assessment of all-cause mortality in an unselected group of consecutive patients with severe COPD (post-bronchodilator FEV1 ≤ 60%).	Outcome measures will be conducted within one year after completion.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of morbidity	Assessment of morbidity: (A) acute exacerbation of COPD, (B) acute non-COPD respiratory events, (C) acute non-respiratory events, (D) cancers, (E) ischemic heart disease (myocardial infarct, angina pectoris, congestive heart failure and arrhythmia) in an unselected group of consecutive patients with severe COPD (post-bronchodilator FEV1 ≤ 60%).	Outcome measures will be conducted within one year after completion.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Monitoring of lung function decline	Monitoring of lung function decline (post-bronchodilator FEV1 will be measured twice a year) and analysis of the differences in patients with specific COPD phenotypes.	Outcome measures will be conducted within one year after completion.
Monitoring of activity of daily living	Measurement of daily activity using pedometers (each participating patient will be monitored for one month, every year) and analysis of the differences in patients with specific COPD phenotypes.	Outcome measures will be conducted within one year after completion.
Monitoring of COPD categories	Assessment of the variability in COPD categories (A-D categories will be calculated twice a year) over a 5 year follow-up and analysis of the differences in patients with specific COPD phenotypes.	Outcome measures will be conducted within one year after completion.
Monitoring of therapeutic compliance	Regular (once a year) monitoring of inhalation technique and evaluation of Morisky Medication Adherence Scale 4 (MMAS-4).	Outcome measures will be conducted within one year after completion.
Monitoring of prognostic indices	Annual monitoring of several prognostic indices (Celli´s BODE, Puhan´s BODE, ADO) and analysis of the differences in patients with specific COPD phenotypes.	Outcome measures will be conducted within one year after completion.
Assessment of the extrapulmonary symptoms	Monitoring of the extrapulmonary impairment (Beck depression scale, Zung depression scale, SNOT-22, densitometry, cardiology history, ECG and cardiac ultrasound) and analysis of the differences in subjects with specific COPD phenotypes.	Outcome measures will be conducted within one year after completion.
Quality of life assessment(SGRQ)	Regular (annual) evaluation of quality of life using SGRQ.	Outcome measures will be conducted within one year after completion.

Collaborators and Investigators

• Sponsor: Zuzana Zbožínková, M.Sc.
• Investigators: Principal Investigator: Vladimir Koblizek, Assoc. Prof. PhD, University Hospital Hradec Kralove

Publications and helpful links

General Publications

• Novotna B, Koblizek V, Zatloukal J, Plutinsky M, Hejduk K, Zbozinkova Z, Jarkovsky J, Sobotik O, Dvorak T, Safranek P. Czech multicenter research database of severe COPD. Int J Chron Obstruct Pulmon Dis. 2014 Nov 10;9:1265-74. doi: 10.2147/COPD.S71828. eCollection 2014.
• Brat K, Svoboda M, Hejduk K, Plutinsky M, Zatloukal J, Volakova E, Popelkova P, Novotna B, Engova D, Franssen FME, Vanfleteren LEGW, Spruit MA, Koblizek V. Introducing a new prognostic instrument for long-term mortality prediction in COPD patients: the CADOT index. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021 Jun;165(2):139-145. doi: 10.5507/bp.2020.035. Epub 2020 Sep 10.

Helpful Links

• Czech National Research Database of COPD

Study record dates

Study Major Dates

• Study Start: August 1, 2013
• Primary Completion (Anticipated): December 1, 2021
• Study Completion (Anticipated): December 1, 2021

Study Registration Dates

• First Submitted: August 7, 2013
• First Submitted That Met QC Criteria: August 13, 2013
• First Posted (Estimate): August 14, 2013

Study Record Updates

• Last Update Posted (Actual): June 13, 2019
• Last Update Submitted That Met QC Criteria: June 12, 2019
• Last Verified: June 1, 2019

More Information

Terms related to this study

• Keywords: COPD; observational; chronic obstructive pulmonary disease; national database
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive
• Other Study ID Numbers: 1301100001 (Other Identifier: State Institute for Drug Control, Czech Republic)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED